Affordable Malaria Vaccine Brings New Hope to Africa

Bharat Biotech and GlaxoSmithKline (GSK) have announced a landmark initiative to reduce the price of their malaria vaccine, Mosquirix (RTS,S), to under $5 per dose by 2028, aiming to make it more accessible across sub-Saharan Africa, where malaria remains a leading cause of child mortality. This move is expected to accelerate the fight against malaria, a disease that claims the lives of more than 260,000 African children under five each year.

A Major Step in Global Health

The vaccine, approved by the World Health Organization (WHO), is the first of its kind to offer protection against malaria, particularly the deadly Plasmodium falciparum strain prevalent in Africa. The price reduction is part of a broader strategy involving a technology transfer from GSK to Bharat Biotech, ensuring the continued supply of the vaccine’s adjuvant and enabling Bharat Biotech to take over full production by 2028. This transition is supported by expanded manufacturing capacity and cost-effective processes, allowing for a gradual price decrease starting immediately.

International Support and Roll-Out

The initiative is backed by Gavi, the Vaccine Alliance, and other international donors, who are funding the vaccine’s distribution in Africa. By the end of this year, twelve African countries are expected to integrate the vaccine into their national immunization programs, with 18 million doses allocated for 2023–2025. Countries such as Ghana, Kenya, and Malawi have already piloted the vaccine, reporting significant reductions in severe malaria cases and child mortality.

Impact and Future Prospects

Experts emphasize that while the vaccine is not a standalone solution, it is a crucial addition to malaria control strategies, complementing existing tools like insecticide-treated nets and seasonal chemoprevention. WHO officials and researchers highlight that the vaccine’s expanded availability could save tens of thousands of young lives each year and help maintain momentum in malaria control efforts, which have recently stagnated due to challenges like the COVID-19 pandemic.

“Any lower cost vaccine means children in the most affected communities in endemic countries can be protected. Sustained affordability is essential to ensuring that the progress we’ve made in malaria control is not only maintained, but accelerated,” said Dr. Kwaku Poku Asante, Director of the Kintampo Health Research Centre.

Disclaimer

This article is based on information available as of June 25, 2025, and summarizes recent developments reported by Devdiscourse and other reputable sources. For the latest updates and medical guidance, readers should consult official health authorities and the World Health Organization.